|Year : 2017 | Volume
| Issue : 1 | Page : 69-74
Spirometry findings among drug users in the Indonesian National Narcotics and illicit drug Bureau Rehabilitation Center
Erlang Samoedro, Faisal Yunus, Budhi Antariksa, Fariz Nurwidya
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of , Persahabatan Hospital, Jakarta, Indonesia
|Date of Web Publication||13-Jan-2017|
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia, Persahabatan Hospital, Jalan Persahabatan Raya No. 1, Rawamangun, Jakarta 13230
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: The increasing prevalence of drug user in Indonesia is affecting the health sectors. The lungs health were affected by the use of the illicit drug. However, lung function among drug users is still unclear. Methods: This descriptive-analytic study involves 144 drug users who met the inclusion criteria. Chest X-ray was performed to identify the subject with pulmonary tuberculosis to exclude from the study. Subjects were then undergone spirometry test and interviewed using questionnaires. Results: One hundred and forty-four subjects were included in this study. One hundred and twenty-one (84.03%) were male and 128 subjects showed normal lung function. Proportion of abnormal spirometry was 10.4% (n = 15). The restriction was found in ten subjects, and obstruction was found in four subjects. There was significant correlation between the ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) and age (P = 0.000; r = −0.454, moderate correlation), time of using cannabis (P = 0.01; r = −0.345, weak correlation), time of using methamphetamine inhalation (P = 0.004; r = −0.25, weak correlation), duration of using heroin injection (P = 0.025; r = −0.337, weak correlation), time of using cigarette (P = 0.000; r = −0.365, weak correlation), and the amount of cigarette consumption/day (P = 0.04; r = −0.238, weak correlation). Conclusion: This study found that there was a weak correlation between declined FEV1/FVC with a time of smoking, the amount of cigarette consume per day, time of cannabis inhalation, time of methamphetamine inhalation, and time of heroin injection.
Keywords: Cannabis, drug abuse, heroin, lung function, methamphetamine
|How to cite this article:|
Samoedro E, Yunus F, Antariksa B, Nurwidya F. Spirometry findings among drug users in the Indonesian National Narcotics and illicit drug Bureau Rehabilitation Center. J Nat Sc Biol Med 2017;8:69-74
|How to cite this URL:|
Samoedro E, Yunus F, Antariksa B, Nurwidya F. Spirometry findings among drug users in the Indonesian National Narcotics and illicit drug Bureau Rehabilitation Center. J Nat Sc Biol Med [serial online] 2017 [cited 2017 May 22];8:69-74. Available from: http://www.jnsbm.org/text.asp?2017/8/1/69/198353
| Introduction|| |
Narcotics and other illicit drugs are still a major problem in Indonesia. The data from National Narcotics Control Bureau of Indonesia in 2004 showed the prevalence of drug abuse is 1.9% of the population. Narcotics drug could depress ventilation through inhibition in the central respiratory system. The depression of respiratory system starts in 7 min after intravenous injection and resume to normal within 2–3 h.
The use of cocaine inhalation significantly reduced lung diffusion capacity marked by decreased diffusing capacity of the lungs for carbon monoxide (DLCo). This is related to the damage of lung structure and has been reported in noncardiogenic lung edema, diffuse alveolar hemorrhage, acute lung edema, interstitial pneumonia, and fibrosis. Cocaine inhalation could damage the alveolar capillary membrane. The cocaine itself could cause the constriction of the pulmonary capillary system. Moreover, embolization of cocaine contaminants in the pulmonary capillary can cause decreased lung diffusion capacity. Heroin could increase the histamine release and several cases of asthma attack developed from heroin inhalation. A study from de los Bueis, et al. shows that the reduced lung diffusion capacity was more prevalent than obstruction.
Drummond et al. revealed in their study that from 974 drug users, 15.5% had an airway obstruction and heroin drug consumption was one of the risk factors to develop chronic obstructive lung disease (COPD). Damage in capillary-alveolar membrane could reduce DLCo. This damage was caused by contaminant particle and vasoconstriction from intravenous cocaine. The assumption that cannabis and cigarette had a similar effect seems reasonable because of their similar psychoactive ingredients: tetrahydrocannabinol and nicotine. However, several studies reported that the effect of cannabis and cigarette was distinguishable. Carbon monoxide and tar deposition were 4–5 times higher in cannabis smoker than cigarettes smoker. The cannabis inhalation method was different from cigarette smoke and was considered as a factor that causes the damage of airway system among cannabis smoker., The assumption that chronic cannabis smoker has the same effect with cigarette smoke was coming from a weak evidence. Since 1970, several studies were conducted to find the evidence of airway obstruction in cannabis smoker. Most of the study failed to establish a relationship between airway obstruction (represented by forced expiratory volume in 1 s [FEV1]) and cannabis smoking. A systematic review performed by Albertson et al. in 2007 showed that the relationship between cannabis smoking and airway obstruction was unconvincing.
There are limited data about the relationship between lung function and history of using amphetamine. Several cases reported panlobular emphysema in methamphetamine injection drug user. Methamphetamine injection was related to pulmonary hypertension which caused by contaminant embolization of pulmonary vascular bed and can form foreign body granuloma. Animal testing showed inhalation methamphetamine increased airway resistance accompanied with reducing serotonin. Children lived near the area of producing methamphetamine showed transient asthma symptoms.
| Methods|| |
This is a cross-sectional study conducted in rehabilitation center of the Narcotics and Illicit Drug User at the National Narcotics Bureau in Lido Sukabumi, Indonesia, from November to December 2012. All recipient were interviewed using questionnaires and performed a spirometry test using SPIROBANK II MIR and compared the data using pneumonia project data as a reference. We recruited 144 rehabilitation patients in a rehab center. Inclusion criteria were a history of using illicit drug or narcotics before entering a rehab center. Exclusion criteria were a patient whose pulmonary X-ray results showed tuberculosis. Unless stated otherwise, numerical data were presented as the mean ± standard deviation and the median (range from minimal to maximal).
| Results|| |
Four recipients were excluded because the X-ray showed suspected tuberculosis. Most of the patient were male 121 (84.3%) and the occupation most of them were unemployed (47.2%). Education level was senior high school 65.3%, and master-degree were 1.4%.
Most of the recipient used multiple illicit drugs. There were four patients that used cannabis smoking and two patients used oral methamphetamine. The mean age of the recipient was 28.19 (±6.02) years, and the mean of body mass index was 23.07 (±4.05) kg/m 2. The mean height of the recipient was 167.4 (±5.91) cm.
Most of the recipients were cigarette smoker, and only two recipients were not an active smoker. The median duration of smoking habit was 12 (±5.33) years. The median number of cigarette consume per day was 6 (±5.33) cigarettes.
Recipient used cannabis smoking were 86 (59.7%). The median duration of cannabis smoking was 10 (±5.01) years and median number of cannabis consumed per day was 3 (±1.85) cannabis.
Methamphetamine user status
Recipient used methamphetamine inhalation were 128 (88.9%) persons. Median duration consuming cannabis were 6 years, ranging from 1 year to 18 years.
Injected heroin status
Recipients used heroin injection were 44 persons (30.6%). The median duration was 14.5 (±5.5) years, ranging from 1 year to 22 years. Median heroin used per day was 0.5 (±0.27) g.
Cocaine inhaled status
Most of the recipients did not use cocaine inhalation, however, there were only three recipients (2.1%) used cocaine inhalation. The duration of using cocaine was 9 (±7) years and cocaine inhalation consumed per day was 0.8 (±0.28) g.
A recipient using methamphetamine oral were 49 persons (34%). The median duration of consuming methamphetamine oral was 7 (±4.34) years, ranging from 1 year to 17 years. Median dose per day of consumption was 2 (±1.36) tablets per day, ranging from 1 tablet to 8 tablets per day.
Last illicit drug used
Most of the recipients (102 persons, 70.8%) used methamphetamine inhalation as the last illicit drug used before rehabilitation.
HIV and another disease status
There were 89 (61.8%) recipients who did not aware of their HIV status, 17 recipients (11.8%) were HIV positive and 38 recipients were HIV negative. Five recipients were asthmatic, and four of them had a childhood history of asthma, while one recipient has no history of asthma during childhood.
Lung functions test
Most of the recipients (129 recipients, 89.6%) showed normal spirometry result, whereas 15 recipients (10.4%) showed abnormal spirometry result. The median of FEV1/forced vital capacity (FVC) ratio was 86.6 (±6.5), ranging from 48.8 to 99.1.
The median %FVC in normal spirometry was 101.80 (±11.1), ranging from 80.30 to 136.6 and the median FEV1/FCV was 86.7 (±4.88), ranging from 75.5 to 98.4 [Table 1].
|Table 1: % forced vital capacity and forced expiratory volume in 1 s/forced vital capacity|
Click here to view
Correlation between spirometry results and illicit drug
Median %FVC of cannabis smoke 86.9 (range: 66.2–99.1), and there was no correlation between median %FVC and cannabis smoking (P = 0.179). Median FEV1/FVC among cannabis users was 98.6 (range: 62.3–136.5), and there was no correlation between FEV1/FVC and cannabis smoking (P = 0.516).
There was no correlation between duration of cannabis smoking and %FVC (P = 0.602). However, there was a weak correlation between duration of cannabis smoking and decline in FEV1/FVC (P = 0.001; r = −0.345) as described in [Figure 1].
|Figure 1: Scatterplot that describes the correlation between cannabis smoking duration and decline of forced expiratory volume in 1 s to forced vital capacity, Spearman's r = −0.345; P = 0.01|
Click here to view
Median %FVC among methamphetamine inhalation users was 99.55 (range: 62.3–138.5), while among nonusers, the median %FVC was 100.6 (79.0–138.5) and there was no correlation between median %FVC in methamphetamine inhalation user and nonuser (P = 0.972). The median FEV1/FVC among methamphetamine user was 86.9 (range: 48.8–99.1), and among nonuser was 85.5 (range: 66.2–98.1). We found no correlation between FEV1/FVC in methamphetamine inhalation user and nonuser (P = 0.243).
No correlation between %FVC and duration of using methamphetamine inhalation (P = 0.372). We found a weak correlation between duration of using methamphetamine inhalation and a decline in FEV1/FVC (P = 0.004; r = −0.250) as described in [Figure 2]. There was no correlation between %FVC and FEV1/FVC amount of methamphetamine used P = 0.061 dan P = 0.81.
|Figure 2: Scatter plot correlation between methamphetamine inhalation user and decline of forced expiratory volume in 1 s to forced vital capacity Spearman correlation test r = −0.25; P = 0.004|
Click here to view
The median % FVC in the heroin intravenous injection group was 100.65 (range: 62.3–136.5), while in nonheroin intravenous user, the median %FVC was 98.5 (range: 67.6–129.6). There was no correlation between median %FVC in heroin intravenous user group and the nonuser group (P = 0.209). Moreover, the median FEV1/FVC in heroin intravenous user group was 84.9 (range: 66.2–92.7), and in nonheroin intravenous user, the median FEV1/FVC was 87.2 (range: 48.8–99.1). We found no correlation between the FEV1/FVC heroin the median FEV1/FVC user group and in the nonuser group (P = 0.243).
There was no correlation between %FVC and duration of using heroin intravenous (P = 0.562). However, we found a weak correlation between duration of using heroin and FEV1/FVC (P = 0.025; r = −0.337) as described in [Figure 3]. No correlation between %FVC and FEV1/FVC with the amount of heroin used (P = 0.197; r = 0.974).
|Figure 3: Scatter plot correlation between duration of using intravenous heroin and decline of forced expiratory volume in 1 s to forced vital capacity (Spearman test r = −0.337; P = 0.025)|
Click here to view
The median %FVC among cocaine inhalation group was 105.6 (range: 102.1–116.3) and in noncocaine inhalation, group was 99.4 (range: 62.3–136.5). There was no correlation between median %FVC in cocaine inhalation user group and the nonuser group (P = 0.221). The median volume ekspirasi paksa satu detik in 1 s/kapasitas vital paksa among cocaine inhalation user group was 90 (range: 84.0–90.2) and in nonuser was 86.6 (range: 48.8–99.1). There was no correlation between the FEV1/FVC in cocaine inhalation user group and nonuser group (P = 0.497). We also found no correlation between the %FVC and FEV1/FVC with the duration of cocaine inhalation used (P = 0.667 and P = 0.667, respectively). There was no correlation between the amount of cocaine used with the %FVC and FEV1/FVC (P = 0.33 and P = 0.33, respectively).
The median %FVC in methamphetamine oral group was 101.8 (range: 67.0–129.6), and in the nonmethamphetamine oral group was 98.6 (range: 62.3–136.5). There was no correlation between the median %FVC in methamphetamine oral user group and the nonuser group (P = 0.765). The median FEV1/FVC in methamphetamine oral user group was 86.7 (range: 48.8–99.1) and in nonmethamphetamine oral user group was 86.6 (range: 71.4–98.1). There was no correlation between the FEV1/FVC in methamphetamine oral user group and the nonuser group (P = 0.966). There was also no correlation between %FVC and FEV1/FVC with the duration of oral methamphetamine used (P = 0.192 and P = 0.066, respectively). There was no correlation between the amount of methamphetamine used with %FVC and FEV1/FVC (P = 0.566 and P = 0.780, respectively).
Correlation between % forced vital capacity and forced expiratory volume in 1 s to forced vital capacity with cigarette smoking
The median %FVC among smoker was 99.85 (range: 62.3–136.5) and in nonactive smoker was 86.1 (range: 67.6–104.7). There was no correlation between median %FVC in the smoker and the nonactive smoker (P = 0.402). The median FEV1/FVC among smoker was 99.8 (range: 66.2–99.1) and in nonactive smoker was 70.95 (range: 40.0–99.1). There was no correlation between FEV1/FVC in the smoker and the nonactive smoker (P = 0.833).
Correlation between % forced vital capacity and forced expiratory volume in 1 s to forced vital capacity with the last used illicit drug
There were correlations between the last used illicit drug cannabis inhalation and methamphetamine inhalation, and between intravenous heroin and oral methamphetamine. In the post hoc analysis, there was a correlation between median %FVC in the last used illicit drug cannabis and intravenous heroin (P = 0.01), cannabis and oral methamphetamine (P = 0.013), methamphetamine inhalation and heroin intravenous (P = 0.034), and finally, methamphetamine inhalation and oral methamphetamine (P = 0.032).
There was no correlation between the median FEV1/FVC and the last illicit drug used (P = 0.278) as described in [Table 2]. There was a correlation between the median %FVC illicit drug used and the route (inhalation, injection, and oral). The post hoc analysis showed a significant correlation between %FVC inhalation and injection route (P = 0.006), inhalation and oral (P = 0.025). There was no correlation between the injection and the oral route (P = 0.407). There was also no correlation between the median FEV1/FVC and the last illicit drug used (P = 0.478).
|Table 2: Correlation between % forced vital capacity and forced expiratory volume in 1 s/forced vital capacity last illicit drug used|
Click here to view
| Discussion|| |
Correlation between % forced vital capacity and forced expiratory volume in 1 s to forced vital capacity with cannabis, methamphetamine inhalation, intravenous heroin, cocaine inhalation, and oral methamphetamine
This study found no correlation between the %FVC and cannabis used, duration and amount of cannabis used. There was a correlation between FEV1/FVC and duration of cannabis used, (P = 0.01; r = −0.345). This result was different with the study from Tashkin, et al. which showed that there was no correlation between the decline of FEV1 and cannabis use. However, a study from Aldington, et al. showed that there was a correlation between cannabis smoking and obstruction of the air flow, hyperinflation, and bronchial damage.
The current study also confirmed that there is no correlation between %FVC and cannabis inhalation, duration and amount per day of using cannabis inhalation. There was a significant correlation between FEV1/FVC with the duration of cannabis inhalation (P = 0.004; r = −0.25). This result showed there was a weak correlation between declined FEV1/FVC and the duration of using cannabis inhalation. There was no correlation between FVC with the duration and amount of using injected heroin. There was a significant correlation between median FEV1/FVC in a subject using injected heroin (84.95) and in noninjected heroin (87.2). This result showed that median FEV1/FVC of injected heroin user was lower than the noninjected heroin group. There was a significant correlation between the FEV1/FVC and the duration of using injected heroin (P = 0.025; r = −0.337), which suggests a weak correlation between FEV1/FVC and duration of using injected heroin. A study from Overland, et al. showed that the prevalence of COPD among injected drug user was 6%. Injected drug users was one of the risk factors for COPD.
We also revealed that there is no correlation between the %FVC and FEV1/FVC with the used of cocaine inhalation and the amount of cocaine consumed per day. This result might cause by the small number of the respondent (n = 3). There was no correlation between the %FVC and FEV1/FVC with the used of oral methamphetamine and amount of methamphetamine consumed per day. This result might suggest that the oral route had less effect to the lung.
Correlation between the % forced vital capacity and forced expiratory volume in 1 s to forced vital capacity with the last illicit drug used
There was significant correlation %FVC from the last illicit drug used between the cannabis inhalation and injected heroin (P = 0.01), and between that cannabis inhalation and oral methamphetamine (P = 0.013). This result showed that there was a significant difference between inhaled cannabis with injected heroin and oral methamphetamine. There was no correlation between the injected heroin and the oral methamphetamine. There was a significant correlation in terms of route of the illicit drug between inhalation route and injected route (P = 0.006) and between inhalation and oral (P = 0.025). There was no correlation between injection route and oral route (P = 0.407).
The proportion of alteration of spirometry test results in the drug users were only 10.4%, and there is a need for a bigger sample to obtain a better analysis. The data were not normally distributed, so we unable to perform multivariate analysis. A bigger sample would be helpful to achieve normal distribution. There were no baseline drug user data to compare; therefore, we used prediction from Indonesian Pneumomobile project. We are unable to determine the most influencing variable because we did not perform multivariate analysis. Drug users were not using only one kind of illicit drug, and that could become a confounder. In this study, we are also unable to exclude the potential confounder. Further cohort or case–control study is needed to confirm our findings in the current study.
| Conclusion|| |
The proportion of spirometry alteration results among drug users were 10.4%, and there was no significant difference from the general population. There was a correlation between declined FEV1/FVC with the duration of cannabis inhalation, methamphetamine inhalation, injected heroin, age, period of smoking, and amount cigarette consumed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Hawari D. Integrated detoxification therapy and boarding school rehabilitation program for drug addict patients. 5th
ed. Jakarta: Penerbit Universitas Indonesia (UI Press); 1999. p. 69-79.
Hind CR. Pulmonary complications of intravenous drug misuse 1. Epidemiology and non-infective complications. Thorax 1990;45:891-8.
Soin JS, Wagner HN Jr., Thomashaw D, Brown TC. Increased sensitivity of regional measurements in early detection of narcotic lung disease. Chest 1975;67:325-30.
Buster MC, Liesbeth R, van Brussel GHA, van Ree J, Wim VD. Chasing the dragon, related to the impaired lung function among heroin users. Ireland: Elsevier; 2002. p. 221-8.
de los Bueis AB, Vega AP, Ramos JLS, Perez JAM, Garcia RA, Jimenez DG, et al
. Bronchial hyperreactivity in patients who inhale heroin mixed with cocaine vaporized on aluminum foil. Chest 2002;121:1223-30.
Drummond MB, Kirk GD, Ricketts EP, McCormack MC, Hague JC, McDyer JF, et al.
Cross sectional analysis of respiratory symptoms in an injection drug user cohort: The impact of obstructive lung disease and HIV. BMC Pulm Med 2010;10:27.
Hind CR. Pulmonary complications of intravenous drug misuse 2. Infective and HIV related complications. Thorax 1990;45:957-61.
Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 1988;318:347-51.
Fligiel SE, Roth MD, Kleerup EC, Barsky SH, Simmons MS, Tashkin DP. Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. Chest 1997;112:319-26.
Roth MD, Arora A, Barsky SH, Kleerup EC, Simmons M, Tashkin DP. Airway inflammation in young marijuana and tobacco smokers. Am J Respir Crit Care Med 1998;157 (3 Pt 1):928-37.
Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: A systematic review. Arch Intern Med 2007;167:221-8.
Albertson TE, Walby WF, Derlet RW. Stimulant-induced pulmonary toxicity. Chest 1995;108:1140-9.
Bishay A, Amchentsev A, Saleh A, Patel N, Travis W, Raoof S. A hitherto unreported pulmonary complication in an IV heroin user. Chest 2008;133:549-51.
Wells SM, Buford MC, Porter VM, Brunell HL, Bunderson-Schelvan M, Nevin AB, et al.
Role of the serotonergic system in reduced pulmonary function after exposure to methamphetamine. Am J Respir Cell Mol Biol 2010;42:537-44.
Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-8.
Tashkin DP, Khalsa ME, Gorelick D, Chang P, Simmons MS, Coulson AH, et al.
Pulmonary status of habitual cocaine smokers. Am Rev Respir Dis 1992;145:92-100.
Aldington S, Williams M, Nowitz M, Weatherall M, Pritchard A, McNaughton A, et al.
Effects of cannabis on pulmonary structure, function and symptoms. Thorax 2007;62:1058-63.
Overland ES, Nolan AJ, Hopewell PC. Alteration of pulmonary function in intravenous drug abusers. Prevalence, severity, and characterization of gas exchange abnormalities. Am J Med 1980;68:231-7.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2]